Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hikma closes NJ facility and tops up supplies from Middle East/North Africa

This article was originally published in Scrip

Executive Summary

The future of Hikma Pharmaceuticals' US generics business is in doubt following its decision to halt production at its Eatontown oral solid dose manufacturing facility in New Jersey after the US FDA said it required additional compliance work. However, Hikma's US customers will continue to be supplied through its FDA-approved manufacturing facilities in the Middle East/North African (MENA) region.

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC019487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel